Home

Salamanca Press

Posts
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER’S DISEASE CONFERENCE (CTAD)
Press Releases
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER’S DISEASE CONFERENCE (CTAD)
Eisai Inc., Clinical Trials for Alzheimer's Disease Conference 
October 23, 2024
TOKYO , Oct. 23, 2024 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") announced today that the company will present t...
Read More...
Local & Social